Related Experiment Video
Updated: Jul 20, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
[Pharmacological treatment of vascular cognitive impairment]
1Klinika Psychiatrii Rozwojowej, Zaburzeń Psychotycznych i Wieku Podeszłego Akademii Medycznej w Gdańsku. kpsych@amg.gda.pl
Abstract:
Vascular dementia is second most common cause of dementia. The paper highlights the most important trends in pharmacological treatment of vascular dementia. Result of a clinical trial of some agents appears to be promising. Pentoxifyline appears to be useful in multi-infarct vascular dementia. Nimodipine produced improvement in subcortical dementia. Some other agents like ginkgo biloba, acetylocholinesterase inhibitors, memantine and other also have shown mild benefit or at least were associated with some stabilization of dementia.
Related Concept Videos
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Dementia l: Introduction
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...